Perioperative Risks and Benefits of Herbal Supplements in Aesthetic Surgery

Aesthetic Surgery Journal

Volumn 29, Issue 2, 2009, Pages 150-157

  Rowe, David J ^a   Baker, Arden C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD CLOTTING; ESTHETIC SURGERY; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; PERIOPERATIVE PERIOD; PLASTIC SURGERY; PRIORITY JOURNAL; QUALITY CONTROL; QUESTIONNAIRE; RISK FACTOR; STANDARDIZATION; WOUND HEALING;

ARNICA; BROMELAINS; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; ECHINACEA; EPHEDRA; GINKGO BILOBA; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; PERIOPERATIVE CARE; PLANT PREPARATIONS; QUALITY CONTROL; RECONSTRUCTIVE SURGICAL PROCEDURES; SURGERY, PLASTIC; VALERIAN;

EID: 64049118808     PISSN: 1090820X     EISSN: 1527330X     Source Type: Journal    
DOI: 10.1016/j.asj.2009.01.002     Document Type: Article

References (97)

1. Garrison F.H. An introduction to the history of medicine, with medical chronology, suggestions for study and bibliographic data (1966), WB Saunders Company, Philadelphia
2. Eisenberg D.M., Davis R.B., Ettner S.L., et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280 (1998) 1569-1575
3. Martin K.J., Jordan T.R., Vassar A.D., and White D.B. Herbal and nonherbal alternative medicine use in Northwest Ohio. Ann Pharmacother 36 (2002) 1862-1869
4. Busse J.W., Heaton G., Wu P., Wilson K.R., and Mills E.J. Disclosure of national product use to primary care physicians: a cross-sectional survey of naturopathic clinic attendees. Mayo Clinic Proc 80 (2005) 616-623
5. Kaye A.D., Clarke R.C., Sabar R., et al. Herbal medicines: current trends in anesthesiology practice-a hospital survey. J Clin Anesth 12 (2000) 468-471
6. Blendon R.J., DesRoches C.M., Benson J.M., Brodie M., and Altman D.E. Americans' views on the use and regulation of dietary supplements. Arch Intern Med 161 (2001) 805-810
7. Elder N.C., Gillcrist A., and Minz R. Use of alternative health care by family practice patients. Arch Fam Med 6 (1997) 181-184
8. Wren K.R., Kimbrall S., and Norred C.L. Use of complementary and alternative medications by surgical patients. J Perianesth Nurs 17 (2002) 170-177
9. Brown S.A., Coimbra M., Coberly D.M., Chao J.J., and Rohrich R.J. Oral nutritional supplementation accelerates skin wound healing: a randomized placebo-controlled, double-arm, crossover study. Plast Reconstr Surg 114 (2004) 237-244
10. Braga P.C., Dal Sasso M., Culici M., Bianchi T., Bordoni L., and Marabini L. Anti-inflammatory activity of thymol: inhibitory effect on the release of human neutrophil elastase. Pharmacology 77 (2006) 130-136
11. Lawrence W.T. Arnica. Plast Reconstr Surg 112 (2003) 1164-1167
12. Widrig R., Suter A., Saller R., and Melzer J. Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study. Rheumatol Int 27 (2007) 585-591
13. Kulik, M. Arnica montana in the reduction of ecchymosis and edema in liposuction. Presented at the 35th Annual American Society for Aesthetic Plastic Surgery Meeting, Las Vegas, NV, April 27-May 3, 2002.
14. Seeley B. Homeopathic Arnica montana in the reduction of ecchymoses after facelift. Presented at the 2002 meeting of the American Academy of Facial Plastic and Reconstructive Surgery, New York, NY.
15. Alonso D., Lazarus M.C., and Baumann L. Effects of topical arnica gel on post-laser treatment bruises. Dermatol Surg 28 (2002) 686-688
16. Totonchi A., and Guyuron B. A randomized, controlled comparison between Arnica and steroids in the management of postrhinoplasty ecchymoses and edema. Plast Reconstr Surg 120 (2007) 271-274
17. Ramelet A.A., Buchheim G., Lorenz P., and Imfeld M. Homeopathic Arnica in postoperative haematomas: a double-blind study. Dermatology 201 (2000) 347-348
18. Lawvere S., and Mahoney M.C. St. John's wort. Am Fam Physician 72 (2005) 2249-2254
19. Shelton R.C., Keller M.B., Gelenberg A., Dunner D.L., Hirschfeld R., Thase M.E., et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 285 (2001) 1978-1986
20. Gaster B., and Holroyd J. St John's wort for depression. Arch Intern Med 160 (2000) 152-156
21. Linde K., Ramirez G., Mulrow C.D., Pauls A., Weidenhammer W., and Melchart D. St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ 313 (1996) 253-258
22. Wagner H., and Bladt S. Pharmaceutical quality of hypericum extracts. J Geriatr Psychiatry Neurol 7 Suppl 1 (1994) S65-S68
23. Ness J., Sherman F., and Pan C.X. Alternative medicine: what the data say about common herbal therapies. Geriatrics 54 (1999) 33-38
24. Neary J.T., and Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res 816 (1999) 358-363
25. Franklin M., Chi J., McGavin C., et al. Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers. Biol Pysychiatry 46 (1999) 581-584
26. Brockmöller J., Reum T., Bauer S., Kerb R., Hübner W.D., and Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30 Suppl 2 (1997) 94-101
27. Schulz H.U., Schürer M., Bässler D., and Weiser D. Investigation of the effect on photosensitivity following multiple oral dosing of two different hypericum extracts in healthy men. Arzneimittelforschung 56 (2006) 212-221
28. Yue Q., Bergquist C., and Gerden B. Safety of St. John's wort. Lancet 355 (2000) 576-577
29. Breidenbach T., Hoffmann M.W., Becker T., Schlitt H., and Klempnauer J. Drug interaction of St. John's wort with cyclosporin. Lancet 355 (2000) 1912
30. Johne A., Brockmöller J., Bauer S., Maurer A., Langheinrich M., and Roots I. Pharmacokinetic interaction in digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 66 (1999) 338-345
31. Woolf R.M., Snow J.W., Walker J.H., and Broadbent T. Resolution of an artificially induced hematoma and the influence of a proteolytic enzyme. J Trauma Injury Infect Crit Care 5 (1965) 491-494
32. Rehman J., Dillow J.M., Carter S.M., Chou J., Le B., and Maisl A.S. Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea andustifolia and Hydrastis canadens is. Immunol Lett 68 (1999) 391-395
33. See D.M., Broumand N., Sahl L., and Tilles J.G. In vitro effects of echinacea and ginseing on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. Immunopharmacology 35 (1997) 229-235
34. Linde K., Barrett B., Wölkart K., Bauer R., and Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 3 (2007) CD000530.
35. Parnham M. Benefit-risk assessment of the squeezed sap of the purple coneflower (Echinacea purpurea) for long term oral immunostimulation. Phytomedicine 3 (1996) 95-102
36. Miller L.G. Herbal medicinals. Arch Intern Med 158 (1998) 2200-2211
37. Hu Z., Yang X., Ho P.C., et al. Herb-drug interactions: a literature review. Drugs 65 (2005) 1239-1282
38. Reuter H.D. Allium sativum and allium ursinum part 2: pharmacology and medicinal applications. Phytomedicine 2 (1995) 73-91
39. Standish L.J., Greene K.B., Bain S., et al. Alternative medicine use in HIV-positive men and women: demographics, utilization patterns, and health status. AIDS Care 13 (2001) 197-208
40. Tang J.L., Armitage J.M., Lancaster T., Silagy C.A., Fowler G.H., and Neil H.A. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 316 (1998) 1213-1221
41. Hebert P.R., Gaziano J.M., Chan K.S., and Hennekens C.H. Cholesterol lowering drugs with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278 (1997) 313-321
42. Ross S.D., Allen I.E., Connelly J.E., et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 159 (1999) 1793-1802
43. Stevinson C., Pittler M.H., and Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med 133 (2000) 420-429
44. Auer W., Eiber A., and Hertkorn E. Hypertension and hyperlipidemia: garlic helps in mild cases. Br J Clin Pract 69 Suppl (1990) 3-6
45. Silagy C.A., and Neil H.A. A meta-analysis of the effect of garlic on blood pressure. J Hypertens 12 (1994) 463-468
46. Ang-Lee M.K., Moss J., and Yuan C.S. Herbal medicines and perioperative care. JAMA 286 (2001) 208-216
47. Srivastava K.C. Evidence for the mechanism by which garlic inhibits platelet aggregation. Prostaglandins Leukot Med 22 (1986) 313-321
48. Apitz-Castro R., Escalante J., Vargas R., and Jain M.K. Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggretory action of prostacclin, forskolin, indomethacin, and dypirimamole on human platelets. Thromb Res 42 (1986) 303-311
49. Hirata J.D., Swiersz L.M., Zell B., Small R., and Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 68 (1997) 981-986
50. Jazieh A.R. Hematologic complications of alternative medicines. Int J Hematol 74 (2001) 405
51. Pittler M.H., and Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 1 (2004) CD002286.
52. Hepinstall S., Groenewegen W.A., Spangenberg P., and Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J Pharm Pharmacol 39 (1987) 459-465
53. Makheja A.N., and Bailey J.M. The active principle in feverfew. Lancet 2 (1981) 1054
54. Le Bars P.L., Katz M.M., Berman N., Itil T.M., Freedman A.M., and Schatzberg A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study group. JAMA 278 (1997) 1327-1332
55. Oken B.S., Storzbach D.M., and Kaye J.A. The efficency of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 55 (1998) 1409-1415
56. Maitra I., Marcocci L., Droy-Lefaix M.T., and Packer L. Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761. Biochem Pharmacol 49 (1995) 1649-1655
57. Chung K.F., Dent G., McCusker M., Guinot P., Page C.P., and Barnes P.J. Effect of a ginkgolide mixture (BN 52063) in antagonizing skin and platelet responses to platelet activating factor in man. Lancet 1 (1987) 248-251
58. Rosenblatt M., and Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 336 (1997) 1108
59. Gurley B.J., Gardner S.F., and Hubbard M.A. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm 57 (2000) 963-969
60. Ling M., Piddlesden S.J., and Morgan B.P. A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement. Clin Exp Immunol 102 (1995) 582-588
61. Bent S., Tiedt T.N., Odden M.C., and Shlipak M.G. The relative safety of ephedra compared with other herbal products. Ann Intern Med 138 (2003) 468-471
62. US Food and Drug Administration Web site. Consumer alert: FDA plans regulation prohibiting sale of ephedra-containing dietary supplements and advises consumers to stop using these products (December 30, 2003). (Accessed January 23, 2009 at http://www.fda.gov/oc/initiatives/ephedra/december2003/advisory.html)
63. Roizen M. Anesthetic implications of concurrent diseases. In: Miller R. (Ed). Anesthesia (1994), Churchill Livingstone, New York
64. Haller C.A., and Benowitz N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 343 (2000) 1833-1838
65. Brekham I., and Dardymov I. New substances of plant origin which increase nonspecific resistance. Annu Rev Pharmacol 9 (1969) 419-430
66. Attele A.S., Wu J.A., and Yuan C.S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58 (1999) 1685-1693
67. Vuksan V., Sievenpiper J.L., Koo V.Y., et al. American ginseng (Panax quinquefolius L.) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med 160 (2000) 1009-1013
68. Beckert B.W., Concannon M.J., Henry S.L., Smith D.S., and Puckett C.L. The effect of herbal medicines on platelet function: an in vivo experiment and review of the literature. Plast Reconstr Surg 120 (2007) 2044-2050
69. Kimura Y., Okuda H., and Arichi S. Effects of various ginseng saponins on 5-hydroxytryptamine release and aggregation in human platelets. J Pharm Pharmacol 40 (1988) 838-843
70. Pepping J. Kava: Piper methysticum. Am J Health Syst Pharm 56 (1999) 957-960
71. Pittler M.H., and Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 20 (2000) 84-89
72. Volz H.P., and Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders-a randomized placebo-controlled 25-week-out patient trial. Pharmacopsychiatry 30 (1997) 1-5
73. Jamieson D.D., Duffield P.H., Cheng D., and Duffield A.M. Comparison of the central nervous system activity of the aqueous and lipid extract of kava (Piper methysticum). Arch Int Pharmacodyn Ther 301 (1989) 66-80
74. Almeida J., and Grimsley E. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 125 (1996) 940-941
75. Russmann S., Barquil Y., Cabalion P., Kritsanida M., Duhet D., and Lauterburg B.H. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol 15 (2003) 1033-1036
76. Center for Food Safety and Applied Nutrition Web site. Consumer advisory. Kava-containing dietary supplements may be associated with severe liver injury (March 25, 2002). (Accessed January 23, 2009, at http://www.cfsan.fda.gov/∼dms/addskava.html.)
77. Houghton P.J. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 51 (1999) 505-512
78. Leathwood P.D., and Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 51 (1985) 144-148
79. Leathwood P.D., Chauffard F., Heck E., and Munoz-Box R. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav 17 (1982) 65-71
80. Leuschner J., Muller J., and Rudmann M. Characterization of the central nervous system depressant activity of a commercially available valerian root extract. Arzneimittelforschung 43 (1993) 638-641
81. Santos M.S., Ferreira F., Cunha A.P., Carvalho A.P., Ribeiro C.F., and Macedo T. Synaptosomal GABA release as influenced by valerian root extract-involvement of the GABA carrier. Arch Int Pharmacodyn Ther 327 (1994) 220-231
82. Garges H., Varia I., and Doraiswamy P. Cardiac complications and delerium associated with valerian root withdrawal. JAMA 280 (1998) 1566-1567
83. Budzinski J.W., Trudeau V.L., Drouin C.E., Panahi M., Arnason J.T., and Foster B.C. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can J Physiol Pharmacol 85 (2007) 966-978
84. Etheridge A.S., Black S.R., Patel P.R., So J., and Mathwes J.M. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 73 (2007) 731-741
85. Gurley B.J., Swain A., Hubbard M.A., et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 52 (2008) 755-763
86. Barnes J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: efficacy and safety. Br J Clin Pharmacol 55 (2003) 331-340
87. Nutrition Labeling and Education Act, 21 USC §343-1 (1990).
88. Dietary Supplement Health and Education act, 21 USC §343-2 (1994).
89. Winslow L.C., and Kroll D.J. Herbs as medicines. Arch Intern Med 1158 (1998) 2192-2199
90. Ashar B.H., Miller R.G., Getz K.J., and Pichard C.P. A critical evaluation of Internet marketing of products that contain ephedra. Mayo Clin Proc 78 (2003) 944-946
91. Angell M., and Kassirer J.P. Alternative medicine-the risks of untested and unregulated remedies. N Engl J Med 339 (1998) 839-841
92. Barnes J. Quality, efficacy and safety of complementary medicines: Fashions, facts and the future. Part I. Regulation and quality. Br J Clin Pharmacol 55 (2003) 226-233
93. Cui J., Garle M., Eneroth P., and Björkhem I. What do commercial ginseing preparations contain?. Lancet 344 (1994) 134
94. Keane F.M., Munn S.E., du Vivier A.W., Taylor N.F., and Higging E.M. Analysis of Chinese herbal creams prescribed for dermatological conditions. BMJ 318 (1999) 563-564
95. Ko R.J. Adulterants in Asian patent medicines. N Engl J Med 339 (1998) 847
96. DeSmet P.A. Herbal medicine in Europe-relaxing regulatory standards. N Engl J Med 352 (2005) 1176-1179
97. Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. 72 Federal Register 34751-34958 (2007) (codified at 21 CFR §111.